Lamotrigine — Antiepileptic / mood stabilizer (phenyltriazine). Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Lamotrigine
Class
Antiepileptic / mood stabilizer (phenyltriazine)
Mechanism
Precise mechanism unknown; proposed inhibition of voltage-sensitive sodium channels, stabilizing membranes and reducing glutamate release.
Used for
Adjunctive treatment of the specified seizure types from age 2; Conversion to monotherapy for partial-onset seizures from age 16 when switching from one of the specifically listed antiseizure medicines; Maintenance of bipolar I disorder in adults after standard treatment of an acute episode
Common side effects
Dizziness; Headache; Diplopia; Ataxia; Nausea
Boxed warning
Lamotrigine can cause life-threatening or fatal rash, including SJS/TEN; serious rash is more frequent in children. Valproate, excessive initial dosing or escalation, and HLA-B*1502 may increase risk. Serious versus benign rash cannot be predicted reliably; the label calls for discontinuation at the first rash unless clearly unrelated to the drug.
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260904 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Antiepileptic mechanism unknown; primidone and its metabolites phenobarbital and PEMA all have anticonvulsant activity.
On both cards: Common side effects — Diplopia; Ataxia; Nausea
Only on the Primidone card: Used for — Grand mal seizures; Psychomotor seizures; Focal epileptic seizures · Common side effects — Vertigo; Drowsiness · Warnings — Contraindicated in porphyria; Phenobarbital hypersensitivity; Rare blood dyscrasias, megaloblastic anemia
Mechanism: Activity is mainly mediated by MHD. The precise anti-seizure mechanism is unknown; in-vitro studies indicate voltage-sensitive sodium-channel blockade that stabilizes hyperexcited membranes.
On both cards: Common side effects — Dizziness; Diplopia; Nausea
Only on the Oxcarbazepine card: Used for — Partial-onset seizures: monotherapy or adjunctive treatment in adults; Partial-onset seizures: monotherapy in children aged 4 years and older; Partial-onset seizures: adjunctive treatment in children aged 2 years and older · Common side effects — Somnolence; Fatigue · Warnings — Hyponatremia; Serious dermatological reactions; Cross-hypersensitivity to carbamazepine · Interactions — Phenytoin; Strong CYP inducers (e.g., carbamazepine); Hormonal contraceptives
Mechanism: The exact analgesic and antiepileptic mechanisms are unknown. Gabapentin is structurally related to GABA but does not affect its binding, uptake or degradation. It binds the alpha-2-delta calcium-channel subunit in vitro; the relevance to therapeutic effects is unknown.
On both cards: Common side effects — Dizziness; Ataxia
Only on the Gabapentin card: Used for — Postherpetic neuralgia in adults; Adjunctive treatment of partial-onset seizures in adults and children aged 3 or older · Common side effects — Somnolence; Peripheral edema; Fatigue · Warnings — DRESS (multiorgan hypersensitivity); Respiratory depression with CNS depressants; Suicidal behavior and ideation · Interactions — Opioids; Antacids (aluminum/magnesium hydroxide)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera